BEIJING (Reuters) – There is no news that new coronavirus modifications will affect vaccine immunity that China has just approved for public use, a disease control official was reported to say Friday.
The bullet by a relative of state-backed Sinopharm company was agreed Thursday, the day after news of the first case brought into China of various spreads spread in Britain. [L1N2JB039]
“There will be no need to panic,” Xu Wenbo, an official at the Chinese Center for Disease Control and Prevention (CDC), said on state TV.
“No change so far has the potential to cause disease,” he said.
He said the effect of any changes on the immune effect of the vaccine was not detected.
The variant named by British scientists “VUI – 202012/01” involves a genetic mutation in the protein “spike”, which could theoretically facilitate the release of COVID-19.
Xu said a mutation in the virus’s protein would not affect the sensitivity of most COVID-19 tests done in China that target the virus’s nuclear acids, which carry genetic information.
Reciting with Roxanne Liu and Ryan Woo; Edited by Andrew Cawthorne